Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts

Journal of Digestive Diseases

Volumn 14, Issue 1, 2013, Pages 29-37

  Tong, Huan ^a   Li, Xiao ^a   Zhang, Chun Le ^a   Gao, Jin Hang ^a   Wen, Shi Lei ^a   Huang, Zhi Yin ^b   Wen, Fu Qiang ^b   Fu, Ping ^b   Tang, Cheng Wei ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Celecoxib; Hepatocellular carcinoma; Octreotide; Transcatheter arterial embolization

Indexed keywords

CD31 ANTIGEN; CELECOXIB; OCTREOTIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GRAFT SURVIVAL; LIVER CELL CARCINOMA; LIVER GRAFT; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ABDOMINAL NEOPLASMS; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; NEOVASCULARIZATION, PATHOLOGIC; OCTREOTIDE; PYRAZOLES; RABBITS; SULFONAMIDES; SURVIVAL RATE;

EID: 84871532638     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12001     Document Type: Article

References (27)

1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009; 3: 353-367.
2. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524.
3. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 2006; 41: 516-521.
4. Marelli L, Stigliano R, Triantos C etal. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
5. Jiang H, Meng Q, Tan H etal. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 2007; 121: 416-424.
6. Liang B, Zheng C, Feng G etal. Experimental evaluation of inhibitory effect of 10-hydroxycamptothecin on hypoxia-inducible factor-1α expression and angiogenesis in liver tumors after transcatheter arterial embolization. J Vasc Interv Radiol 2010; 21: 1565-1572.
7. Breinig M, Schirmacher P, Kern MA. Cyclooxygenase-2 (COX-2) - a therapeutic target in liver cancer? Curr Pharm Des 2007; 13: 3305-3315.
8. Zhao QT, Yue SQ, Cui Z etal. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci 2007; 80: 484-492.
9. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006; 32: 28-44.
10. Cheng AS, Chan HL, To KF etal. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 2004; 24: 853-860.
11. Reubi JC, Zimmermann A, Jonas S etal. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999; 45: 766-774.
12. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42: 442-447.
13. Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: current management. Curr Probl Surg 2010; 47: 10-67.
14. Tang C, Liu C, Zhou X, Wang C. Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer 2004; 112: 470-474.
15. Xie Y, Chen S, Wang CH, Tang CW. SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. Cancer Biol Ther 2011; 12: 86-92.
16. 188Rhenium-HDD-labeled iodized oil in rabbit VX2 liver tumor. J Vasc Interv Radiol 2004; 15: 1121-1128.
17. Deng J, Rhee TK, Sato KT etal. In vivo diffusion-weighted imaging of liver tumor necrosis in the VX2 rabbit model at 1.5 Tesla. Invest Radiol 2006; 41: 410-414.
18. Liu Z, Chang Q, Xu ZL, Zhang ZG. Stereological measurement of rat's seminiferous tubule. Chin Med J (Engl) 2009; 122: 2643-2646.
19. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773.
20. Park Y, Choi D, Lim HK etal. Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT. AJR Am J Roentgenol 2008; 191: 215-220.
21. Llovet JM, Di Bisceglie AM, Bruix J etal; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
22. Golfieri R, Cappelli A, Cucchetti A etal. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5cm) hepatocellular carcinomas. Hepatology 2011; 53: 1580-1589.
23. Hashimoto T, Nakamura H, Hori S etal. Hepatocellular carcinoma: efficacy of transcatheter oily chemoembolization in relation to macroscopic and microscopic patterns of tumor growth among 100 patients with partial hepatectomy. Cardiovasc Intervent Radiol 1995; 18: 82-86.
24. Jaeger HJ, Mehring UM, Castañeda F etal. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 1996; 19: 388-396.
25. Pleguezuelo M, Marelli L, Misseri M etal. TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 2008; 8: 1623-1641.
26. Xiao EH, Guo D, Bian DJ. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 4582-4586.
27. Liang B, Zheng CS, Feng GS etal. Correlation of hypoxia-inducible factor 1α with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. Cardiovasc Intervent Radiol 2010; 33: 806-812.